Research programme: epigenetic targeted therapeutics - IgnytaAlternative Names: Autoimmune disorder therapeutics - Ignyta; Cancer therapeutics - Actagene Oncology/Ignyta; Immuno-oncology therapeutics - Ignyta; Spark-1; Spark-1 Rx/Dx Program; Spark-2; Spark-2 Rx/Dx Program; Spark-3; Spark-3 Rx/Dx Program
Latest Information Update: 10 Oct 2014
At a glance
- Originator Actagene-Oncology; Ignyta
- Developer Ignyta
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer